A late relapse thymoma and pure red cell aplasia case with an over 5 years of clinical response under everolimus.
Journal
Anti-cancer drugs
ISSN: 1473-5741
Titre abrégé: Anticancer Drugs
Pays: England
ID NLM: 9100823
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
medline:
1
11
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
ppublish
Résumé
Although several agents showed some clinical activity in patients with recurrent thymoma, there is no standard treatment option. Here, we report a late relapse thymoma and pure red cell aplasia case, responsive to everolimus with over 5 years of clinical benefit following multiple lines of treatment. Everolimus controlled the rapidly progressive disease in our patient without significant toxicity.
Identifiants
pubmed: 37823284
doi: 10.1097/CAD.0000000000001504
pii: 00001813-202311000-00016
doi:
Substances chimiques
Everolimus
9HW64Q8G6G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1193-1195Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010; 5(10 Suppl 4):S260–S265.
Zhao Y, Shi J, Fan L, Hu D, Yang J, Zhao H. Surgical treatment of thymoma: an 11-year experience with 761 patients. Eur J Cardiothorac Surg 2016; 49:1144–1149.
National Comprehensive Cancer Network. Thymomas and thymic carcinomas (Version 2.2022). https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf. [Accessed 1 December 2022]
Kondo K. Optimal therapy for thymoma. J Med Invest 2008; 55:17–28.
Detterbeck FC, Zeeshan AT. Current diagnosis and treatment. Chin Med J (Engl) 2013; 126:2186–2191.
Okuma Y, Saito M, Hosomi Y, Sakuyama T, Okamura T. Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. J Cancer Res Clin Oncol 2015; 141:323–331.
Schmitt J, Loehrer PJ Sr. The role of chemotherapy in advanced thymoma. J Thorac Oncol 2010; 5(10 Suppl 4):S357–S360.
Girard N. Chemotherapy and targeted agents for thymic malignancies. Expert Rev Anticancer Ther 2012; 12:685–695.
Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M, et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol 2018; 36:342–349.
Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 2015; 16:177–186.
Liang Y, Padda SK, Riess JW, West RB, Neal JW, Wakelee HA. Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Lung Cancer 2015; 87:34–38.
Longo F, De Filippis L, Zivi A, Vitolo D, Del Signore E, Gori B, et al. Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: results of a pilot trial. Am J Clin Oncol 2012; 35:105–109.
Loehrer PS, Wang W, Johnson DH, Aisner SC, Ettinger DS. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004; 22:293–299.
Palmieri G, Merola G, Federico P, Petillo L, Marino M, Lalle M, et al. Preliminary results of phase II study of capecitabine and gemcitabine [CAP-GEM] in patients with metastatic pretreated thymic epithelial tumors [TETs]. Ann Oncol 2010; 21:1168–1172.
Highley MS, Underhill CR, Parnis FX, Karapetis C, Rankin E, Dussek J, et al. Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 1999; 17:2737–2744.
Zarogoulidis P, Lampaki S, Turner JF, Huang H, Kakolyris S, Syrigos K, et al. mTOR pathway: a current, up-to-date mini-review. Oncol Lett 2014; 8:2367–2370.
Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitör with clinical applications in organ transplantation, oncology and cardiology. Pharmacotherapy 2010; 30:1044–1056.
Hellyer JA, Ouseph MM, Padda SK, Wakelee HA. Everolimus in the treatment of metastatic thymic epithelial tumors. Lung Cancer 2020; 149:97–102.
Means RT Jr. Pure red cell aplasia. Blood 2016; 128:2504–2509.
Palmieri G, Buonerba C, Federico P, Formisano L, Nappi L, Di Lorenzo G, et al. Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies. World J Clin Oncol 2012; 3:111–115.